Chargement en cours...
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
BACKGROUND: Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3878047/ https://ncbi.nlm.nih.gov/pubmed/24359526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-604 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|